StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK): Raising PT To $72 - UBS
July 31, 2017 8:12 AM
UBS analyst, Marc Goodman, reiterated his Buy rating on shares of Merck (NYSE: MRK) and raised his price target to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
July 31, 2017 9:41 AM